- Friday, August 4, 2023
9:00 AM – 9:15 AM ET
Welcome
9:00 AM – 9:15 AM ET
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 9:15 AM – 9:30 AM ET
18 - Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOX
9:15 AM – 9:30 AM ET
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - FOLFIRINOXPresenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Presenter###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Presenter: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 9:30 AM – 9:45 AM ET
18 - Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOX
9:30 AM – 9:45 AM ET
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - NALIRIFOXPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 9:45 AM – 10:00 AM ET
18 - Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer
9:45 AM – 10:00 AM ET
Session 15: Debate: NALIRIFOX or FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Cancer - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – MD Anderson Cancer Center, The University of Texas
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Panelist###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Panelist: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Panelist###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Panelist: – MD Anderson Cancer Center, The University of Texas
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 10:30 AM ET
15 - Session 16: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Yes
10:15 AM – 10:30 AM ET
Session 16: Debate: Is There a Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - YesPresenter: – Northwell Health Cancer Institute
Joseph Herman, MD, MSc, MHCM (he/him/his) – Northwell Health Cancer Institute ### 1849663###Presenter###Director of Clinical Research###Northwell Health Cancer Institute###Presenter: – Northwell Health Cancer Institute
### he/him/his10:30 AM – 10:45 AM ET
15 - Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - No
10:30 AM – 10:45 AM ET
Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - NoPresenter: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
Lisa Kachnic, MD (she/her/hers) – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center ### 1849664###Presenter###Professor and Chair, Department of Radiation Oncology###Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center###Presenter: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
### she/her/hers10:45 AM – 11:00 AM ET
15 - Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - Discussion
10:45 AM – 11:00 AM ET
Session 16: Debate: Is There A Role for Radiation Therapy in Borderline-Resectable Pancreatic Cancer? Yes vs No - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – Northwell Health Cancer Institute
Panelist: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Joseph Herman, MD, MSc, MHCM (he/him/his) – Northwell Health Cancer Institute ### 1849663###Panelist###Director of Clinical Research###Northwell Health Cancer Institute###Panelist: – Northwell Health Cancer Institute
### he/him/his @@@ Lisa Kachnic, MD (she/her/hers) – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center ### 1849664###Panelist###Professor and Chair, Department of Radiation Oncology###Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center###Panelist: – Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
### she/her/hers11:00 AM – 11:15 AM ET
Break
11:00 AM – 11:15 AM ET
Break
11:15 AM – 11:50 AM ET
19 - Session 17: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment Strategies
11:15 AM – 11:50 AM ET
Session 17: Improving the Management of Cholangiocarcinoma: Adopting Recent NCCN Guidelines to Improve Patient Care in Diagnosis, Molecular Testing, and Targeted Treatment StrategiesPresenter: – MD Anderson Cancer Center, The University of Texas
Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Presenter###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Presenter: – MD Anderson Cancer Center, The University of Texas
### 11:50 AM – 12:00 PM ET
19 - Live Q&A
11:50 AM – 12:00 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – MD Anderson Cancer Center, The University of Texas
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Milind M. Javle, MD – MD Anderson Cancer Center, The University of Texas ### 944699###Speaker###Professor of Medicine###MD Anderson Cancer Center, The University of Texas###Speaker: – MD Anderson Cancer Center, The University of Texas
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:05 PM ET
21 - Session 18: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and Gastric
12:30 PM – 1:05 PM ET
Session 18: Rising Incidence of Early-Onset GI Malignancies: Pancreatic, CRC, and GastricPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### 1:05 PM – 1:15 PM ET
21 - Live Q&A
1:05 PM – 1:15 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Vanderbilt-Ingram Cancer Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Speaker###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Speaker: – Vanderbilt-Ingram Cancer Center
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:15 PM ET
Session 19: Determination of Treatment Patterns in HCCPresenter: – Memorial Sloan Kettering Cancer Center
1:30 PM – 2:15 PM ET
Session 19: Determination of Treatment Patterns in HCCPresenter: – Memorial Sloan Kettering Cancer Center
Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center ### 697827###Presenter###Professor###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 2:15 PM – 2:30 PM ET
Break
2:15 PM – 2:30 PM ET
Break
2:30 PM – 3:15 PM ET
Session 20: Role of Interventional Radiology in the Management of NETsPresenter: – Stanford School of Medicine
2:30 PM – 3:15 PM ET
Session 20: Role of Interventional Radiology in the Management of NETsPresenter: – Stanford School of Medicine
Nishita Kothary, MD – Stanford School of Medicine ### 1001596###Presenter###Professor###Stanford School of Medicine###Presenter: – Stanford School of Medicine
### 3:15 PM – 3:30 PM ET
Break
3:15 PM – 3:30 PM ET
Break
3:30 PM – 4:15 PM ET
20 - Session 21: Significance of Cancer Genetics
3:30 PM – 4:15 PM ET
Session 21: Significance of Cancer GeneticsPresenter: – University of Chicago
Sonia Kupfer, MD (she/her/hers) – University of Chicago ### 1849665###Presenter###Associate Professor of Medicine###University of Chicago###Presenter: – University of Chicago
### she/her/hers4:15 PM – 4:20 PM ET
20 - Closing Remarks
4:15 PM – 4:20 PM ET
Closing RemarksCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
###
